OVERALL SURVIVAL (OS) AND CLINICAL OUTCOMES IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH AZACITIDINE (AZA) OR LOW-DOSE CYTARABINE (LDAC) IN THE AZA-AML-001 STUDY

被引：0
|
作者：
Seymour, J. F. [1 ]
Doehner, H. [2 ]
Kumar, R. [3 ]
Stone, R. M. [4 ]
Wierzbowska, A. [5 ]
Bernal del Castillo, T. [6 ]
Falantes, J. [7 ]
Delaunay, J. [8 ]
Sabloff, M. [9 ,10 ]
Voso, M. T. [11 ]
Kim, I. [12 ]
Ram, R. [13 ]
Gau, J. P. [14 ]
Songer, S. [15 ]
Lucy, L. M. [15 ]
Beach, C. [15 ]
Dombret, H. [16 ]
机构：
[1] Peter MacCallum Canc Ctr, East Melbourne, Australia
[2] Univ Ulm Klinikum, Ulm, Germany
[3] Canc Care Manitoba, Winnipeg, MB, Canada
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Med Univ Lodz, Lodz, Poland
[6] Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain
[7] Hosp Univ Virgen del Rocio, Inst BioMed Sevilla, Seville, Spain
[8] CHU Nantes, Hotel Dieu, F-44035 Nantes 01, France
[9] Univ Ottawa, Ottawa, ON, Canada
[10] Ottawa Hosp, Res Inst, Ottawa, ON, Canada
[11] Univ Roma Tor Vergata, Rome, Italy
[12] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[13] Rabin Med Ctr, Petah Tiqwa, Israel
[14] Taipei Vet Gen Hosp, Taipei, Taiwan
[15] Celgene Corp, Summit, NJ USA
[16] Univ Paris Diderot, Inst Univ Hematol, Hop St Louis, Paris, France
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E954
引用
收藏
页码：381 / 381
页数：1
相关论文
共 50 条
  • [21] Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)
    Huante, Emmanuel Almanza
    Kantarjian, Hagop
    Chien, Kelly S.
    DiNardo, Courtney D.
    Short, Nicholas
    Maiti, Abhishek
    Montalban-Bravo, Guillermo
    Daver, Naval
    Kawedia, Jitesh D.
    Bowie, Kayleigh
    Pierce, Sherry A.
    Ravandi, Farhad
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    BLOOD, 2022, 140 : 3344 - 3346
  • [22] Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)
    Huante, Emmanuel Almanza
    Bataller, Alex
    Hammond, Danielle E.
    Chien, Kelly S.
    DiNardo, Courtney D.
    Short, Nicholas J.
    Maiti, Abhishek
    Montalban-Bravo, Guillermo
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    BLOOD, 2023, 142
  • [23] AZACITIDINE (AZA) VS. CONVENTIONAL TREATMENT REGIMENS (CTR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (>30% BONE MARROW BLASTS) WITH MYELODYSPLASIA-RELATED CHANGES: A SUBGROUP ANALYSIS OF AZA-AML-001
    Bernal, T.
    Dombret, H.
    Doehner, H.
    Lucy Lela, M.
    Beach, C. L.
    McCallum, P.
    HAEMATOLOGICA, 2015, 100 : 134 - 135
  • [24] ASSOCIATION OF MIR29 RNA WITH RESPONSE AND SURVIVAL IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH AZACITIDINE (AZA) OR CONVENTIONAL CARE REGIMENS (CCR)
    MacBeth, K. J.
    Tang, L.
    Seymour, J. F.
    Stone, R. M.
    Minden, M. D.
    Lucy, L. M.
    Beach, C.
    Doehner, H.
    HAEMATOLOGICA, 2015, 100 : 317 - 317
  • [25] Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with Morphologic Dysplastic Changes: A Subgroup Analysis of the AZA-AML-001 Trial
    Seymour, John F.
    Doehner, Hartmut
    Butrym, Aleksandra
    Wierzbowska, Agnieszka
    Selleslag, Dominik
    Jang, Jun Ho
    Cavenagh, James D.
    Kumar, Rajat
    Schuh, Andre C.
    Candoni, Anna
    Recher, Christian
    Sandhu, Irwindeep
    Bernal del Castillo, Teresa
    Al-Ali, Haifa Kathrin
    Martinelli, Giovanni
    Falantes, Jose
    Stone, Richard M.
    Minden, Mark D.
    McIntyre, Heidi
    Songer, Stephen
    Lucy, Lela M.
    Beach, C. L.
    Dombret, Herve
    BLOOD, 2014, 124 (21)
  • [26] Effects of obesity on overall survival (OS) of patients with acute myeloid leukemia (AML).
    Dhakal, Prajwal
    Lyden, Elizabeth
    Lee, Andrea
    Michalski, Joel
    Al-Kadhimi, Zaid S.
    Maness, Lori J.
    Gundabolu, Krishna
    Bhatt, Vijaya Raj
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Phase II Trial Of Cladribine and Low-Dose AraC (LDAC) Alternating With Decitabine In Older Patients With Acute Myeloid Leukemia (AML)
    Kadia, Tapan M.
    Borthakur, Gautam
    Ferrajoli, Alessandra
    Jain, Preetesh
    Jabbour, Elias
    Verstovsek, Srdan
    Pemmaraju, Naveen
    Faderl, Stefan
    Ravandi, Farhad
    Konopleva, Marina
    Tuttle, Carla
    Brandt, Mark
    Wang, Xuemei
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    BLOOD, 2013, 122 (21)
  • [28] PHASE II EVALUATION OF VOLASERTIB (BI 6727) + LOW-DOSE CYTARABINE (LDAC) VERSUS LDAC MONOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): FOCUS ON GENETIC RESULTS
    Doehnert, H.
    Luebbert, M.
    Fiedler, W.
    Fouillard, L.
    Haaland, A.
    Brandwein, J.
    Lepretre, S.
    Reman, O.
    Turlure, P.
    Bug, G.
    Mueller-Tidow, C.
    Kraemer, A.
    Voss, F.
    Taube, T.
    Maertens, J.
    HAEMATOLOGICA, 2013, 98 : 247 - 247
  • [29] EFFICACY AND SAFETY OF AZACITIDINE (AZA) VERSUS CONVENTIONAL TREATMENT (TC) IN PATIENTS=75 YEARS WITH ACUTE MYELOBLASTIC LEUKEMIA (AML) IN THE PHASE III STUDY AZA AML001
    Bargay Lleonart, J.
    Seymour, J. F.
    Buckstein, R.
    Santini, V
    Doehner, H.
    Stone, R. M.
    Minden, M. D.
    Ching, Kuo Y.
    Ben Yehuda, D.
    Songer, S.
    Weaver, J.
    Beach, C. L.
    Dombret, H.
    HAEMATOLOGICA, 2017, 102 : 176 - 177
  • [30] HOSPITALIZATION FOR TREATMENT-EMERGENT ADVERSE EVENTS (TEAE) IN OLDER (≥65 YEARS) PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WITH >30% MARROW BLASTS IN THE PHASE 3 AZA-AML-001 STUDY
    Seymour, J. F.
    Doehner, H.
    Stone, R. M.
    Gambini, D.
    Dougherty, D.
    Weaver, J.
    Beach, C.
    Dombret, H.
    HAEMATOLOGICA, 2016, 101 : 219 - 220
12345